SCHEMBL31662292

SCHEMBL31662292

CC(C)Oc1ncc(F)c2nc(OC[C@@]34CCCN3C[C@H](F)C4)nc(N)c12

nearest known ligand 0.51

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ KRAS P01116 20/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31662335 0.80 KRAS (0.47) KRAS
SCHEMBL29418868 0.79 KRAS (0.49) KRAS
SCHEMBL29418852 0.79 KRAS (0.49) KRAS
SCHEMBL30825546 0.76 KRAS (0.53) KRAS
SCHEMBL31662314 0.75 KRAS (0.45) KRAS
SCHEMBL31662295 0.75 KRAS (0.49) KRAS
SCHEMBL30229810 0.74 KRAS (0.57) KRAS
SCHEMBL31662256 0.74 KRAS (0.42) KRAS
SCHEMBL31662255 0.74 KRAS (0.42) KRAS
SCHEMBL29679980 0.73 KRAS (0.47) KRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151594-A1 FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF KESTREL THERAPEUTICS INC. (US) 2025-07-17 — — WO disclosed
Send feedback